Skip to Content
PD-L1  /  PDCD1LG1  /  CD274  /  B7-H1  (Cancer  Immunotherapy  Target)  (PDL1/2746) ,   Biotin  conjugate ,   0.1mg / mL

PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) , Biotin conjugate , 0.1mg / mL

https://www.glycotech.com/web/image/product.template/197733/image_1920?unique=2421920
(0 review)
PD-L1 (also known as Programmed Death Ligand 1 , CD274 , and B7-H1) is one of two cell surface ligands that engage the negative regulatory T cell surface receptor PD-1. PD-L1 is a Type I transmembrane protein expressed on the plasma membrane of cells , such as activated macrophages and some tumor cells. Because binding of PD-1 by PD-L1 has a suppressive effect on the immune system , inhibition of the PD-1/PD-L1 pathway is a major strategy of immune-oncology therapies. PD-L1 is upregulated in certain cancers , and blocking PD-1 or PD-L1 can inhibit cancer growth._x000D_ _x000D_ Primary antibodies are available purified , or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets , because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors._x000D_ _x000D_

0.01 € 0.01 EUR 0.01 € Tax Excluded

0.01 € Tax Excluded

Not Available For Sale

(0.00 € / Units)

This combination does not exist.

Terms and Conditions
30-day money-back guarantee
Shipping: 2-3 Business Days


Internal Reference: BNCB2746-100
Website URL: /shop/bncb2746-100-pd-l1-pdcd1lg1-cd274-b7-h1-cancer-immunotherapy-target-pdl1-2746-biotin-conjugate-0-1mg-ml-197733